Nutriband faces a precarious financial outlook characterized by volatile revenue streams and a structural inability to achieve profitability, as evidenced by a TTM operating margin of -408.41%. The company's reliance on external capital to fund its AVERSA prog...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled.
ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th.
Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval.
ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit on Aug 26th as part of the CEO spotlight event.
Benchmark NTRB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nutriband Inc. (NTRB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.35 | $89.35M | -2.85 | -4.83% | -404.08% | -125.56% | — | |
| $0.81 | $12.02M | -0.67 | 10429.36% | -804.37% | -748.08% | — | |
| $21.64 | $2.1B | -42.43 | 504.79% | -0.11% | -0.33% | — | |
| $18.72 | $779.27M | -654.55 | 6.85% | 0.66% | 1.17% | — | |
| $2.05 | $25.08M | -0.25 | — | — | -165.71% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — |
Nutriband Inc. (NTRB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Nutriband Inc. (NTRB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 22, 2026·SEC
Apr 7, 2026·SEC
Feb 13, 2026·SEC
Get notified when NTRB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nutriband Inc. (NTRB) stock FAQ — growth, dividends, profitability & financials explained
Nutriband Inc. (NTRB) reported $1.6M in revenue for fiscal year 2025.
Nutriband Inc. (NTRB) saw revenue decline by 4.8% over the past year.
Nutriband Inc. (NTRB) reported a net loss of $7.0M for fiscal year 2025.
Nutriband Inc. (NTRB) has a return on equity (ROE) of -125.6%. Negative ROE indicates the company is unprofitable.
Nutriband Inc. (NTRB) had negative free cash flow of $3.6M in fiscal year 2025, likely due to heavy capital investments.
